Immupharma PLC NEW NUCANT PATENTS (6443J)

TIDMIMM

RNS Number : 6443J

Immupharma PLC

16 June 2014

 
 FOR IMMEDIATE RELEASE : RNS    16 JUNE 2014

NEW NUCANT PATENTS

- New Optically Pure Compounds for Improved Therapeutic Efficiency -

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is delighted to announce that the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of ImmuPharma's Nucant family. A similar grant has been obtained from the EU, Japanese and Australian patent offices.

The patent was developed by ImmuPharma in collaboration with the CNRS (Centre National de la Recherche Scientifique), the largest fundamental research institution in Europe with which ImmuPharma has its key research collaboration. This composition of matter patent importantly provides:

   --     Longer exclusivity 
   --     Additional and reinforced protection of ImmuPharma's Nucant programme 
   --     A multitude of further indications in addition to cancer

This new patent family covers millions of peptide constructs (i.e. preventing other companies from working in the area) and also expands the potential uses to include angiogenesis related conditions such as age-related macular degeneration, diabetic retinopathy and wound healing as well as cancer selective targeting systems (Nucants target selectively the cancer cells through binding to nucleolin, a protein over expressed in cells that proliferate quickly).

The patent exclusive rights belong to ELRO Pharma, one of ImmuPharma's wholly owned subsidiaries. ELRO Pharma is focusing on pioneering research related to this Nucant family of molecules.

Dr Robert Zimmer, ImmuPharma's President and Chief Scientific Officer and one of the inventors of the patent commented: "We are pleased to see our research efforts rewarded and to add to our extensive patent portfolio. It is important for us to keep ahead of innovation in the industry and this broadens the company's pipeline and takes us in new exciting areas of unmet medical need".

For further information please contact:

 
 ImmuPharma plc                               + 44 (0) 20 7152 4080 
 Dimitri Dimitriou, Chief Executive 
  Officer 
 Dr Robert Zimmer, President and Chief 
  Scientific Officer 
 Richard Warr, Chairman 
 Lisa Baderoon, Head of Investor Relations     + 44 (0) 7721 413496 
 
 Panmure, Gordon & Co., NOMAD & Broker         +44 (0) 20 7886 2500 
 Hugh Morgan 
  Fred Walsh

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCQKNDQABKDNAD

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024